|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Celera Group (NYSE:CRA), a molecular diagnostics developer. |
|---|---|
| Transferring Party | Berkeley HeartLab, Inc., a cardiovascular healthcare company with a broad portfolio of CLIA certified tests and disease management services for the secondary prevention market. |
| Sector | Diagnostics |
| Date | October 15, 2007 |
| Analysis Provides Celera with CLIA-certified laboratory and infrastructure to commercialize its portfolio of new molecular diagnostic tests that predict risk and individualize treatment in cardiovascular disease. The personalized cardiovascular disease management market is growing at more than 10% per year. The deal is expected to accelerate Celera’s path to profitability (BHL's EBITDA margins were 17% in 06). Deal value - $195m. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |